- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01920256
Provider-Initiated Regular Remote Interventions for Optimal Type 2 Diabetes Care
Patients with type 2 diabetes can attain superior disease outcomes if multiple therapy goals are simultaneously achieved and maintained. In reality, therapy goals are seldom achieved, and patients become susceptible to devastating complications and greater health care expenses. Studies have shown that regular monitoring and therapy adjustments are a prerequisite to achieving and maintaining therapy goals. Unfortunately implementation of regular monitoring and therapy adjustments have been hindered by high clinic workload and shortage of endocrinologists. Due to this shortage, endocrine care is accessible to less than 20% of patients with type 2 diabetes. The overwhelming majority are managed by providers who may lack the necessary expertise or time to deliver optimal disease management, particularly when insulin is prescribed.
Objectives: We hypothesize that type 2 diabetes endocrine clinics for high-risk patients that complement primary care, personalize the frequency of remote disease interventions and employ infrequent face-to-face outpatient visits, will achieve comparable clinical outcomes and patient satisfaction compared to usual endocrine clinic care, while reducing workload and increasing the clinic capacity. The intervention clinic will employ regular remote communications initiated by the endocrinologists, based on tailored individual plans. Frequent remote monitoring and interventions will reinforce attainment of the therapy goals and allow a decrease in the frequency of outpatient visits. In turn, the clinic workload will decrease and it will be able to accommodate more patients with type 2 diabetes than traditional endocrine clinics. The aims of the study are to test this new endocrine clinic model in a clinical trial by monitoring clinical parameters, patient satisfaction and clinical workload. The long-term objectives are to modify the current model of endocrine care for patients with type 2 diabetes.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan Health System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men or women aged ≥18 years of age;
- Clinical diagnosis of type 2 diabetes (as defined by the American Diabetes Association 2);
- Treated with insulin or at least two diabetes medications;
- Have A1C ≥8.0% and ≤11.0%;
- Able and willing to use telephone or other sorts of communication regularly between clinic visits.
Exclusion Criteria:
- Do not speak English;
- Unwilling or unable to provide informed consent;
- Have any condition associated with life expectancy of less than 3 years;
- Have an active mental illness or substance abuse
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Personalized type 2 diabetes care.
Remote, personalized type 2 diabetes clinic provided by an endocrinologist using frequent remote contacts for medication adjustments.
|
Diabetes and comorbidities will be managed with 1 clinic visit per year and frequent adjustments made remotely.
|
Active Comparator: Usual Endocrine Care
Usual Endocrine care will be provided by an endocrinologist.
|
Diabetes and comorbidities management will provided by an endocrinologist
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in baseline A1C (glycated hemoglobin) at 12 months
Time Frame: 12 months
|
Measure of long-term blood glucose control and efficacy of intervention
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in baseline lipids at 12 months
Time Frame: 12 months
|
Measure of total cholesterol, LDL, and Triglycerides
|
12 months
|
Change in baseline blood pressure at 12 months
Time Frame: 12 months
|
Systolic and diastolic blood pressure
|
12 months
|
All cause mortality
Time Frame: 12 months
|
Record deaths due to any cause
|
12 months
|
Acute complications
Time Frame: 12 months
|
Cardiovascular events, cerebrovascular events, peripheral vascular events, limb ulcers and amputations, severe hypoglycemia, and other unscheduled emergency department and hospital visits
|
12 months
|
Change in baseline Quality of life at 12 months
Time Frame: 12 months
|
Short Form-36
|
12 months
|
Change in baseline insulin satisfaction at 12 months
Time Frame: 12 months
|
Insulin Therapy Satisfaction Questionnaire
|
12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinic retention
Time Frame: 12 months
|
Missed visits, missed phone calls, lost to follow up and drops outs will be recorded for both groups
|
12 months
|
Cost
Time Frame: 12 months
|
Resource utilization and cost for both groups
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Israel Hodish, MD, PhD, University of Michigan
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UMichigan
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on Remote, personalized type 2 diabetes care.
-
University of OxfordNIHR Collaboration for Leadership in Applied Health Research and Care (Oxford)CompletedType 2 Diabetes MellitusUnited Kingdom
-
University of ChicagoAmerican Diabetes AssociationCompleted
-
Better TherapeuticsCompletedType 2 DiabetesUnited States
-
MajianhuaUnknown
-
Sheba Medical CenterHebrew University of JerusalemCompletedType 2 Diabetes | Aging | Cognitive DeclineIsrael
-
Fundacio d'Investigacio en Atencio Primaria Jordi...CompletedType 2 Diabetes | Cardiovascular Risk Factor | GenderSpain
-
Fundacio d'Investigacio en Atencio Primaria Jordi...Unknown
-
University of ArkansasActive, not recruitingDiabetes Mellitus, Type 2 | Food InsecurityUnited States
-
Harran UniversityCompletedDiabetic Foot | Diabete Type 2Turkey
-
Université de SherbrookeUniversity of Manitoba; University of TorontoCompletedDiabetes, GestationalCanada